PISCATAWAY, N.J., – International research outsourcing company GenScript Corporation has announced the launch of a new series of antibodies specifically tailored to neuroscience research.
GenScript’s neuroscience antibodies target many proteins and peptides associated with neurological diseases. “These high-quality neuroscience antibodies,”
These antibodies, particularly the ones applicable to studies involving the various pathways leading to neurological diseases, are among the bio-reagents most sought by researchers. Many of GenScript's neuroscience antibody production processes involve affinity chromatography purification based on the relevant epitope. This further ensures the quality of the antibodies generated. GenScript has a comprehensive collection of antibodies targeting Alzheimer’s disease. In addition, GenScript provides antibodies for neurological diseases including Parkinson’s disease, amyotrophic lateral sclerosis, and Huntington’s disease.
GenScript neurological antibodies can be used in Western blots, immunohistochemistry, immunoprecipitation, and ELISA. Meanwhile, most of these antibodies can be delivered in trial-sized packages.
GenScript Corporation is a reliable outsourcing partner providing a wide array of services to augment all stages of the drug discovery and biological reagent manufacturing processes, including high-quality gene synthesis and cloning, custom protein expression and purification, custom peptide synthesis and antibody development, custom stable cell line development, and a wide selection of biological reagents to life science researchers in industrial and academic settings. GenScript Corporation is headquartered in Piscataway, New Jersey.
http://www.genscript.com/
